Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.

Alzheon, based in Framingham, Massachusetts, filed with the U.S. Securities and Exchange Commission to launch an initial public offering (IPO).